[Effects of idebenone on monoamine metabolites in the cerebrospinal fluid of patients with cerebrovascular dementia].
Elucidation of the alterations of intracerebral neurotransmitters in cerebrovascular dementia is of prime importance not only in revealing patho-physiological mechanism but also in developing the therapy for the disease. We measured monoamine metabolites and norepinephrine (NE) in cerebrospinal fluid of patients with cerebrovascular dementia, to study the effects of administration of 6-(10-hydroxydecyl)-2, 3-dimethoxy-5-metyl-1,4-benzoquinone (idebenone, CV-2619). Six patients with cerebral infarction and 1 with cerebral hemorrhage, at the mean age of 65.4 years, were enrolled as subjects. All patients had mental and intelligent impairment, and the Hasegawa's Dementia Rating (DR) Scale was performed. The patients were medicated with 90 mg daily dose of CV-2619 for 1 to 2 months, and homovanillic acid (HVA), 5-hydroxyindole acetic acid (5-HIAA), 3-methoxy-4-hydroxyphenylethylenglycol (MHPG), NE in cerebrospinal fluid were determined by high-performance liquid chromatography before and also after the medication. Before the medication, HVA was 21.7 +/- 1.4 ng/ml (mean +/- SE), which was significantly low (p less than 0.01), compared with controls at a similar age: 5-HIAA was 18.5 +/- 2.7 ng/ml, and MHPG, 9.5 +/- 0.7 ng/ml, both of which were not significantly low, but tended to be low, compared with the controls. NE was similar to the control value. With the administration of CV-2619, HVA measured 27.1 +/- 3.2 ng/ml, showing a tendency to increase; 5-HIAA was 26.7 +/- 2.3 ng/ml, and MHPG, 10.7 +/- 0.6 ng/ml, both of which increased significantly (p less than 0.05), compared with the respective premedication values.(ABSTRACT TRUNCATED AT 250 WORDS)
M
M
Kawakami
T
T
Itoh
D000368:Aged; D016227:Benzoquinones; D001679:Biogenic Amines / Q000378:metabolism*; D002561:Cerebrovascular Disorders / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D002851:Chromatography, High Pressure Liquid; D003704:Dementia / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid; D008875:Middle Aged; D009638:Norepinephrine / Q000134:cerebrospinal fluid; D011809:Quinones / Q000627:therapeutic use*; D014451:Ubiquinone / Q000031:analogs & derivatives
D016227:Benzoquinones; D001679:Biogenic Amines; D011809:Quinones; D014451:Ubiquinone; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; C036619:idebenone; D009638:Norepinephrine; D006719:Homovanillic Acid